OPTHHealthcare · Drug Manufacturers - Specialty & GenericOPTH Stock Forecast: Optimi Health Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 1 Aug 2026 — in the weakest quartile.
OPTH stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Optimi Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Optimi Health Corp. — and when they’d sell — is the membership.
OPTH stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OPTH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OPTH analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Optimi Health Corp. (OPTH) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −4.0×
- Price / sales
- 117.7×
- Price / book
- 6.2×
- EV / EBITDA
- −9.7×
Cheaper than 88% of US stocks
Cheaper than 4% of US stocks
Cheaper than 17% of US stocks
Cheaper than 84% of US stocks
- Revenue growth (YoY)
- 62.5%
- Earnings growth (YoY)
- 62.5%
- Gross margin
- 89.9%
- Operating margin
- −1033.7%
- Net margin
- −16.0%
Higher than 90% of US stocks
Higher than 81% of US stocks
Higher than 97% of US stocks
Higher than 6% of US stocks
Higher than 17% of US stocks
- Return on equity
- −88.7%
- Return on assets
- −20.3%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OPTH vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPTH appears on the weeks it earns a place.
Frequently asked questions about OPTH stock
How does Ticker Nerd's model rank OPTH?
As at 1 Aug 2026, Optimi Health Corp. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
What is the OPTH stock forecast for 2030?
No analyst covering Optimi Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPTH are extrapolating price history, which says nothing about the business.
What does Optimi Health Corp. do?
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on the manufacturing and distribution of regulated psychedelic drug products.
About Optimi Health Corp.
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on the manufacturing and distribution of regulated psychedelic drug products. The company produces finished-dose psilocybin and MDMA capsules, along with active pharmaceutical ingredients, at a Health Canada-licensed, GMP-compliant facility in British Columbia. Its products are supplied to authorized clinical and therapeutic programs, supporting patient access through regulated channels in markets such as Australia and Canada. Optimi Health Corp. serves the growing mental health treatment ecosystem by providing standardized drug products for psychiatrists, clinics, and research programs that require controlled, pharmaceutical-grade supply. The company also develops related product formats within its licensed manufacturing platform, reinforcing its role as a specialized supplier in the pharmaceutical and life sciences sectors.
CEO Mr. Dane Stevens · 6 employees · Canada · https://www.optimihealth.ca